vilobelimab

Vilobelimab is a chimeric human-mouse monoclonal IgG4 kappa antibody that specifically binds to the soluble complement split product C5a, a potent pro-inflammatory mediator generated during activation of the complement system. By binding to C5a with high affinity and blocking its interaction with the C5a receptor, vilobelimab inhibits downstream inflammatory responses such as increased vascular permeability, cytokine release, and neutrophil recruitment. It is developed primarily for severe COVID-19 in hospitalized adults requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO), where it aims to reduce inflammation-driven lung injury. Vilobelimab has also been investigated for other inflammatory conditions including pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). The drug was granted emergency use authorization by the FDA in April 2023 for COVID-19 and received marketing authorization in the European Union in January 2025[2][3][5][7][9].

Brand names

Gohibic

Other names

vilobelimab-InflaRx